Amount of eligible patients: CDEC discussed the uncertainty in the volume of individuals with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients who're categorized as getting mild or aver